2024/10/18 17:38:50 | |
---|---|
Price | |
509.40 EUR | |
Difference | 1.31% (6.60) |
ISIN | NL0010832176 |
Symbol | ARGX |
Exchange | Euronext Brussels |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 30,460 EUR |
Benchmark | AMSTERDAM EXCHANGES INDEX |
Bid (Bid size) | 500.40 EUR (250) |
Ask (Ask size) | 510.00 EUR (66) |
Open | 503.80 EUR |
High | 509.60 EUR |
Low | 500.00 EUR |
Close (prev. day) | 502.80 EUR |
VWAP | 506.989077 EUR |
Volume (pcs) | 45,059 |
Trading volume | 22,844,421.00 |
Number of trades | 2,214 |
Last size | 1 |
Related Futures | 21 |
Related Options | - |
Date | Headline | Download | |
2024/10/08 | Global Strategy 4Q 2024 | ||
2024/09/27 | Global Equity Ratings | ||
2024/09/11 | Global Equity Ratings | ||
2024/08/12 | Global Equity Ratings | ||
2024/07/03 | Global Strategy 3Q 2024 |
2024/10/18 17:38:50 | |
---|---|
Price | |
509.40 EUR | |
Difference | 1.31% (6.60) |
ISIN | NL0010832176 |
Symbol | ARGX |
Exchange | Euronext Brussels |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 30,460 EUR |
Benchmark | AMSTERDAM EXCHANGES INDEX |
Bid (Bid size) | 500.40 EUR (250) |
Ask (Ask size) | 510.00 EUR (66) |
Open | 503.80 EUR |
High | 509.60 EUR |
Low | 500.00 EUR |
Close (prev. day) | 502.80 EUR |
VWAP | 506.989077 EUR |
Volume (pcs) | 45,059 |
Trading volume | 22,844,421.00 |
Number of trades | 2,214 |
Last size | 1 |
6m | 1Y | 3Y | |
Perf (%) | +50.32% | +10.95% | +103.79% |
Perf (abs.) | +172.60 | +50.90 | +262.60 |
Beta | 0.39 | 0.54 | 0.40 |
Volatility | 35.40 | 45.77 | 42.87 |
Ø price 5 days | Ø volume 5 days (pcs.) | 501.50 EUR (45,274) |
Ø price 30 days | Ø volume 30 days (pcs.) | 487.01 EUR (57,322) |
Ø price 100 days | Ø volume 100 days (pcs.) | 445.73 EUR (60,962) |
Ø price 250 days | Ø volume 250 days (pcs.) | 402.77 EUR (63,352) |
YTD High | date | 509.60 EUR (2024/10/18) |
YTD Low | date | 322.50 EUR (2024/03/20) |
52 Weeks High | date | 509.60 EUR (2024/10/18) |
52 Weeks Low | date | 271.00 EUR (2023/12/20) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Vienna Stock Exchange | 2024/10/18 | 15:30 | 503.20 EUR | 0.00 | 4 |
Tradegate | 2024/10/18 | 22:26 | 519.80 EUR | 0.02 | 3 |
Stuttgart | 2024/10/18 | 13:25 | 500.20 EUR | 0.00 | 8 |
Munich | 2024/10/18 | 08:05 | 502.00 EUR | 0.00 | 2 |
London Stock Exchange European Trade Reporting | 2024/10/18 | 17:30 | 503.50 EUR | 0.00 | 2 |
Frankfurt | 2024/10/18 | 08:03 | 499.60 EUR | 0.00 | 2 |
FINRA other OTC Issues | 2024/09/05 | 20:52 | 525.6012 USD | 0.06 | 4 |
Euronext Milan MTF Trading After Hours | - | - | - | 0.00 | - |
Euronext Brussels | 2024/10/18 | 17:38 | 509.40 EUR | 22.84 | 2,214 |
Duesseldorf | 2024/10/18 | 08:12 | 499.90 EUR | 0.00 | 3 |
Berlin | 2024/10/18 | 19:33 | 514.80 EUR | 0.00 | 16 |
ARGENX SE |
- - |
Laarderhoogtweg 25 - 1101 EB Amsterdam |
Telefon: +31-76-303-04-88 |
Fax: + |
E-mail: info@argenx.com |
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands. |
Tim Van Hauwermeiren | Chairman of Managing Board |
Andria Wilk | Member of Executive Committee |
Arjen Lemmen | Member of Executive Committee |
Beth DelGiacco | Member of Executive Committee |
Filip Borgions | Member of Executive Committee |
Karen Massey | Member of Executive Committee |
Karl Gubitz | Member of Executive Committee |
Luc Truyen | Member of Executive Committee |
Malini Moorthy | Member of Executive Committee |
Marc Schorpion | Member of Executive Committee |
Peter Ulrichts | Member of Executive Committee |
Peter K. M. Verhaeghe | Chairman of Supervisory Board |
Ana Cespedes | Member of Supervisory Board |
Brian Kotzin | Member of Supervisory Board |
Joseph deBethizy | Member of Supervisory Board |
Pamela Klein | Member of Supervisory Board |
Anthony Adam Rosenberg | Member of Supervisory Board |
Camilla Sylvest | Member of Supervisory Board |
James Daly | Member of Supervisory Board |
Steve Krognes | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer